New research from the American Society for Clinical Oncology 2013 Annual Meeting:
Men’s Fitness in Middle Age Protects Against Developing and Dying from Cancer Later in Life
(ASCO) Findings from a large, prospective 20-year study indicate that a high level of cardiovascular...
read more...
May 20th, 2013
New research from the American Society for Clinical Oncology 2013 Annual Meeting
(ASCO) A phase I expansion study of the investigational drug
MPDL3280A – an engineered PD-L1 targeted antibody – shows impressive tumor
shrinkage rates in patients with several different cancers –...
read more...
May 16th, 2013
New published research funded by UALC
Personalized,
targeted therapies can offer prolonged survival and fewer side effects for
patients whose tumors have specific genetic alterations. However, most patients
will eventually become resistant to treatment with targeted drugs....
read more...
May 14th, 2013
Professional guidelines recommend all patients with advanced-stage lung adenocarcinoma be tested for EGFR and ALK, regardless of clinical history
Personalized medicine is the future of oncology. New targeted treatments can offer prolonged survival and fewer side effects for...
read more...
April 25th, 2013
Share with friends:
Share on Twitter Share on Facebook Share on Google+